MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements joined Proactive's Stephen Gunnion with details of the company's activity in the first quarter of 2023, as well as upcoming milestones.
Clements noted that clinical trials of its CimetrA drug continue to demonstrate anti-inflammatory effects, with the results set to be used in a US new drug submission, adding that the US market holds significant potential for the company.
This year, he said the company will also focus on expanding access to CannEpil in Europe, and advancing its cannabinoid-based investigational products.